Stocktoria
Elicio Therapeutics, Inc. ELTX
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2021-02-05
Elicio Therapeutics, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | $2.3M | $28.3M |
| R&D expense | $24.9M | $33.7M | $23.8M | $18.1M | $48.7M |
| Operating income | -$37.7M | -$45.0M | -$35.7M | -$23.7M | -$39.3M |
| Interest expense | — | — | $1.1M | $3.6M | — |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$39.6M | -$51.9M | -$35.2M | -$28.2M | -$54.6M |
| EPS (diluted) | $-2.58 | $-4.25 | $-6.96 | $-89.27 | $-1.93 |
| Operating cash flow | -$37.0M | -$37.1M | -$32.7M | -$22.2M | -$52.6M |
| Free cash flow | -$37.0M | -$37.2M | -$32.8M | -$22.8M | -$53.0M |
| Cash & equivalents | $18.6M | $17.6M | $12.9M | $6.2M | $88.8M |
| Total assets | $25.9M | $28.2M | $27.1M | $22.7M | $96.5M |
| Total liabilities | $24.2M | $39.5M | $15.8M | $13.7M | $15.0M |
| Shareholders' equity | $1.6M | -$11.3M | $11.4M | -$102.1M | -$74.5M |
Source: SEC EDGAR filings · CIK 0001601485 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.